Biodesix Net Income 2011-2026 | BDSX

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Biodesix

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-42.9 M	-52.1 M	-65.4 M	-43.2 M	-65.4 M	-30.7 M	-26.2 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-26.2 M	-65.4 M	-46.6 M

Quarterly Net Income Biodesix

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-8.72 M	-11.5 M	-11.1 M	-	-10.3 M	-10.8 M	-13.6 M	-	-10.9 M	-13.4 M	-18.7 M	-	-13.7 M	-15.8 M	-15.6 M	-	-11.5 M	-11.4 M	-6.96 M	-	-8.84 M	-8.27 M	-9.71 M	-	-9.6 M	-6.86 M	-7.74 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-6.86 M	-18.7 M	-11.2 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Diagnostics research industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
Centogene N.V. CNTG	-46.9 M	-	-6.23 %	$ 30.6 M	Germany
Biomerica BMRA	-4.97 M	$ 2.16	1.41 %	$ 4.96 M	USA
Bioventus BVS	22.7 M	$ 9.15	1.67 %	$ 610 M	USA
Akumin AKU	-157 M	-	-17.87 %	$ 25.9 M	Canada
Fulgent Genetics FLGT	-42.7 M	$ 16.34	0.06 %	$ 494 M	USA
Guardant Health GH	-416 M	$ 83.59	-1.54 %	$ 10.5 B	USA
Enzo Biochem ENZ	-26.1 M	-	-8.98 %	$ 14.8 K	USA
Check-Cap Ltd. CHEK	-25.1 M	-	-	$ 9.42 M	Israel
Heska Corporation HSKA	-19.9 M	-	-	$ 1.31 B	USA
HTG Molecular Diagnostics HTGM	-21.6 M	-	-20.0 %	$ 1.06 M	USA
Oxford Immunotec Global PLC OXFD	-1.81 M	-	-	$ 562 M	Britain
ICON Public Limited Company ICLR	791 M	$ 101.28	0.93 %	$ 8.35 B	Irlanda
IDEXX Laboratories IDXX	1.06 B	$ 570.21	-1.43 %	$ 45.9 B	USA
DermTech DMTK	-101 M	-	-11.32 %	$ 2.94 M	USA
Aspira Women's Health AWH	-27.2 M	-	-6.19 %	$ 10.5 M	USA
Lantheus Holdings LNTH	234 M	$ 74.24	-1.97 %	$ 5.01 B	USA
Co-Diagnostics CODX	-35.3 M	$ 4.4	101.83 %	$ 129 M	USA
Accelerate Diagnostics AXDX	-14.6 M	-	-61.36 %	$ 2.46 M	USA
Medpace Holdings MEDP	451 M	$ 460.74	0.83 %	$ 13.3 B	USA
Global Cord Blood Corporation CO	501 M	-	-	$ 399 M	China
Motus GI Holdings MOTS	-12.9 M	-	-34.28 %	$ 263 K	Israel
Fluidigm Corporation FLDM	-53 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	-7.13 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	-503 M	-	0.12 %	$ 80.1 M	China
Mettler-Toledo International MTD	869 M	$ 1 264.46	1.94 %	$ 26.1 B	Schweiz
Myriad Genetics MYGN	-366 M	$ 4.61	-1.07 %	$ 427 M	USA
National Research Corporation NRC	11.6 M	$ 17.44	-0.4 %	$ 390 M	USA
PRA Health Sciences, Inc. PRAH	197 M	-	-	$ 10.7 B	USA
Natera NTRA	-548 M	$ 194.52	-2.78 %	$ 19.1 B	USA
Charles River Laboratories International CRL	-144 M	$ 159.19	0.75 %	$ 7.89 B	USA
IQVIA Holdings IQV	1.36 B	$ 166.09	-0.52 %	$ 28.6 B	USA
Organovo Holdings ONVO	-2.49 M	-	-2.3 %	$ 19.4 M	USA
OpGen OPGN	12 M	-	-16.95 %	$ 1.54 M	USA
Pacific Biosciences of California PACB	-546 M	$ 1.39	-	$ 417 M	USA
Biocept BIOC	-32.1 M	-	-13.05 %	$ 7.29 M	USA
Invitae Corporation NVTA	-99.8 M	-	-	$ 21.2 M	USA
BioNano Genomics BNGO	-26.4 M	$ 1.18	-19.18 %	$ 6.43 M	USA
Interpace Biosciences IDXG	6.7 M	$ 1.71	0.73 %	$ 7.5 M	USA
Illumina ILMN	-1.22 B	$ 125.98	1.77 %	$ 20 B	USA
Personalis PSNL	-81.3 M	$ 7.78	2.23 %	$ 461 M	USA
QIAGEN N.V. QGEN	83.6 M	-	-	$ 10.6 B	Niderland
Precipio PRPO	-5.85 M	$ 26.6	-1.23 %	$ 34.5 M	USA
RadNet RDNT	-18.7 M	$ 59.87	-3.03 %	$ 4.5 B	USA
Celcuity CELC	-112 M	$ 102.01	-4.44 %	$ 4.02 B	USA
Chembio Diagnostics CEMI	-23.3 M	-	0.22 %	$ 16.8 M	USA
Laboratory Corporation of America Holdings LH	876 M	$ 266.12	0.64 %	$ 22.1 B	USA
ENDRA Life Sciences NDRA	-11.5 M	$ 3.46	-0.57 %	$ 1.86 M	USA
NeoGenomics NEO	-108 M	$ 7.86	-2.96 %	$ 1.01 B	USA
Renalytix AI plc RNLX	-33.5 M	-	5.66 %	$ 22.7 M	Britain